Abdur Rafay Bilal

Abdur Rafay Bilal

Auto-generated profile, based on publicly available information

Abdur Rafay Bilal

Ziauddin Medical University Karachi Pakistan

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2025 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Open access
ABAbdur Rafay Bilal
Abdur Rafay Bilal
MSMaryam Sajid
Maryam Sajid
SQShaheer Qureshi
Shaheer Qureshi
HGHateem Gaba
Hateem Gaba
RAReja Ahmad
Reja Ahmad
SWSaad Ahmed Waqas
Saad Ahmed Waqas
Heart failure (HF) and stroke remain among the leading causes of cardiovascular mortality in the U.S. However, the intersection of these two conditions has been underexplored in national mortality data. This study investigates temporal, demographic, and geographic trends in stroke-related deaths among individuals with HF from 1999 to 2023. Using the CDC WONDER database, we extracted multiple cause-of-death records for adults ≥25 years where both HF and stroke were listed. Age-adjusted mortality rates (AAMRs) per 100,000 were calculated using the 2000 U.S. standard population. Joinpoint regression identified significant trends and calculated average annual percent changes (AAPCs). From 1999 to 2023, 465,695 deaths were attributed to both HF and stroke. AAMRs declined steadily from 13.46 in 1999 to a low of 7.19 in 2019 (AAPC: -3.2%; 95% CI: -3.3 to -3.0; p < 0.001) but then increased to 8.69 by 2023. Men had consistently higher AAMRs than women (2023: 9.88 vs. 7.71). NH Black individuals experienced the highest AAMRs (13.79 in 2023), slower declines, and an earlier mortality crossover compared to other groups. Adults aged 25-44 exhibited the steepest increase. Geographically, the South and rural counties bore the highest burden. Despite long-term mortality declines, recent reversals-especially post-pandemic and among younger, male, and racially minoritized populations-signal urgent gaps in equity and access.

21 February 2026 in Endocrinology, Diabetes & Metabolism
Verified
Journal Article
Open access
ABAbdur Rafay Bilal
Abdur Rafay Bilal
MIMuhammad Ibrahim
Muhammad Ibrahim
SAS. M. Washaqul Arfin
S. M. Washaqul Arfin
ABAbdur Raheem Bilal
Abdur Raheem Bilal
RBRahul Balach
Rahul Balach
SWSaad Ahmed Waqas
Saad Ahmed Waqas
Background: Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) have demonstrated promising effects in promoting weight loss and improving metabolic markers. However, their effectiveness post‐bariatric surgery remains uncertain. Methods: PubMed, Cochrane CENTRAL, and Scopus were queried through March 2025 for randomised controlled trials comparing GLP‐1RA to placebo in post‐bariatric surgery patients. Outcomes included weight loss, BMI, total cholesterol, triglycerides, fasting blood glucose, blood pressure, HbA1c, and adverse events. Random‐effects models were used to calculate standardised mean differences (SMDs), weighted mean differences (WMDs), and risk ratios (RRs). Results: Six trials ( n = 401) were included. GLP‐1RA significantly reduced weight (SMD: −5.96 kg [95% CI: −9.40, −2.53]; p = 0.0007), BMI (WMD: −3.08 kg/m 2 [95% CI: −4.16, −2.00]; p < 0.00001), total cholesterol (WMD: −0.30 mmol/L / −11.60 mg/dL [95% CI: −0.50, −0.09 / −19.34, −3.48]; p = 0.005), and HbA1c (WMD: −0.39% [95% CI: −0.62, −0.17]; p = 0.0007). Total adverse events (RR: 1.49 [95% CI: 1.14, 1.94]; p = 0.003) and nausea (RR: 2.23 [95% CI: 1.21, 4.09]; p = 0.010) were more common with GLP‐1RA compared to placebo. No significant changes were found in blood pressure, triglycerides, or fasting blood glucose. Conclusions: GLP‐1RAs significantly reduce weight, BMI, HbA1c, and total cholesterol in patients following bariatric surgery. These findings highlight the potential of GLP‐1RA therapy post‐bariatric surgery. Future research is warranted to assess the long‐term effects of GLP‐1RA on the post‐operative metabolic profile.

13 March 2026 in Endocrinology, Diabetes & Metabolism
Verified
Journal Article
Open access
DADua Ali
Dua Ali
ABAbdur Rafay Bilal
Abdur Rafay Bilal
SAS. M. Washaqul Arfin
S. M. Washaqul Arfin
MSMaryam Sajid
Maryam Sajid
SQShaheer Qureshi
Shaheer Qureshi
SWSaad Ahmed Waqas
Saad Ahmed Waqas
Aims: To evaluate the efficacy and safety of closed‐loop automated insulin delivery (AID) systems with the conventional insulin delivery arm in adults with type 2 diabetes mellitus (T2DM). Methods: A systematic review and meta‐analysis of 10 randomised controlled trials ( n = 786; AID: 436, control: 350) was conducted per PRISMA guidelines. Data from studies were pooled using a random‐effects model to derive weighted mean differences (WMDs) and 95% confidence intervals (CIs). Results: AID significantly increased time in normoglycemia (WMD: +22.14%; 95% CI: 17.05, 27.23; 319 min/day; P < 0.00001) and reduced hyperglycemia (WMD: −21.04%; 95% CI: −6.23, −15.84; −303 min/day; P < 0.00001), mean glucose (WMD: −1.54 mmol/L; 95% CI: −2.37, −0.70; P = 0.0003), and HbA1c (WMD: −0.80%; 95% CI: −1.48, −0.12; P < 0.00001). Glucose SD improved significantly (WMD: –0.46; 95% CI: −0.74, −0.18; P = 0.002). No significant differences were found in hypoglycemia (WMD: −0.11%; 95% CI: −0.32, 0.09; −1.6 min/day; P = 0.28), total daily insulin (WMD: +4.80 IU; 95% CI: −1.87, 11.47; P = 0.16), or CV (WMD: −0.52%; 95% CI: −2.08, 1.04; P = 0.52). Total adverse events were higher with AID (RR: 1.61; 95% CI: 1.20, 2.17; P = 0.002), but serious adverse events (RR: 1.61; 95% CI: 0.83, 3.13; P = 0.16) and severe hypoglycemia (OR: 2.13; 95% CI: 0.22,20.83; P = 0.52) were not significantly different. Conclusions: Closed‐loop AID significantly improves glycemic control in T2DM without increasing serious adverse events.